| |
| |
|
| Insider
Information: |
Gergen Mark J |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
657,039 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,206,613 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
657,039 |
|
|
| Total
Value |
$2,206,613 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amylin Pharmaceuticals Inc |
AMLN |
SVP, Corporate Develop... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
Executive VP, COO |
2016-01-15 |
5,748 |
2016-01-15 |
0 |
Premium* |
|
|
Poseida Therapeutics, Inc. |
PSTX |
|
2024-03-01 |
651,291 |
2022-02-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PSTX |
Poseida Therapeutics, Inc... |
Executive Chairman |
• • – |
2024-03-01 |
4 |
D |
$4.13 |
$141,068 |
D/D |
(34,157) |
651,291 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
Executive Chairman |
• • – |
2024-02-01 |
4 |
D |
$3.41 |
$160,822 |
D/D |
(47,162) |
685,448 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
Executive Chairman |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
732,610 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
President and CEO |
• • – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
269,586 |
601,610 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
President and CEO |
• • – |
2023-02-01 |
4 |
D |
$7.00 |
$222,733 |
D/D |
(31,819) |
330,314 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
President and CEO |
• • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
357,200 |
357,200 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Executive VP, COO |
• – – |
2016-01-15 |
4 |
OE |
$8.50 |
$127,500 |
D/D |
15,000 |
15,748 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Executive VP, COO |
• – – |
2016-01-15 |
4 |
S |
$25.92 |
$259,211 |
D/D |
(10,000) |
5,748 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-08-08 |
4 |
D |
$31.00 |
$328,085 |
I/I |
(10,583) |
0 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-08-08 |
4 |
D |
$31.00 |
$1,648,611 |
D/D |
(53,181) |
0 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-08-08 |
4 |
A |
$31.00 |
$1,648,611 |
D/D |
53,181 |
53,181 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-08-08 |
4 |
D |
$31.00 |
$2,007,256 |
D/D |
(64,750) |
0 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-07-25 |
4 |
A |
$14.62 |
$13,684 |
D/D |
936 |
64,750 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
63,814 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-03-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,529 |
7,974 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate DevelopmentSVP, |
• – – |
2012-03-01 |
4 |
S |
$17.11 |
$31,585 |
D/D |
(1,846) |
53,814 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate Development |
• – – |
2012-02-08 |
4 |
D |
$16.47 |
$51,601 |
D/D |
(3,133) |
42,344 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate Development |
• – – |
2012-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
45,477 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate Development |
• – – |
2012-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
37,477 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate Development |
• – – |
2011-03-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,630 |
6,445 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Corporate Development |
• – – |
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
21,666 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP Corporate Development |
• – – |
2010-02-03 |
4 |
A |
$17.83 |
$7,346 |
D/D |
412 |
6,079 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP Corporate Development |
• – – |
2010-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,360 |
4,815 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Sr VP Corporate Development |
• – – |
2009-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
2,550 |
3,455 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Sr VP Corporate Development |
• – – |
2009-02-03 |
4 |
A |
$11.80 |
$6,903 |
D/D |
585 |
4,506 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
